AstraZeneca Pharma shares gain on pediatric drug launch in India
The company already received Import and Market Permission in Form CT-20 from the Drugs Controller General of India.10-08-2023
10-08-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Launch Of Selumetinib 10 Mg And 25 Mg Capsule (Koselugo)
We refer to our earlier communication dated September 26, 2021 intimating the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Selumetinib 10 mg and 25 mg capsule (Koselugo). With regard to the same, we now wish to further update that AstraZeneca Pharma India Limited has launched Koselugo in India. Selumetinib (Koselugo) is indicated for treatment of Pediatric patients 3 years of age and older with neurofibromatosis type 1 (NF1) and who have symptomatic, inoperable plexiform neurofibromas (PN).09-08-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Monday, August 14, 2023
ASTRAZENECA PHARMA INDIA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2023 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2023. We would also like to inform you that the 'Trading Window' remains closed for all Designated Persons, from June 16, 2023 to August 16, 2023 (both days inclusive) in terms of AstraZeneca Pharma India Limited - Code of Conduct for Prevention of Insider Trading framed under Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015.04-08-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith the Certificate dated August 2, 2023 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming the compliance of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.04-08-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Business Responsibility and Sustainability Reporting (BRSR)
Pursuant to Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Business Responsibility and Sustainability Report for the financial year 2022-23, which also forms par of the Annual Report for financial year 2022-23.04-08-2023
Glenmark gets USFDA nod to market generic diabetes drug
The company has received final approval from the US Food Drug Administration (US FDA) for Saxagliptin Tablets (2.5 mg and 5 mg), the generic version of AstraZeneca's Onglyza1 tablets, the Mumbai-based drug maker said in a statement.01-08-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Information Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Change In Senior Management
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you on the change in role of Mr. Atul Tandon, Business Unit Head - Oncology. He will be transitioning from the said role with effect from close of business hours on July 31, 2023, as he takes up another responsibility within AstraZeneca group. In the interim, the Oncology Business Unit of the Company will be managed by Mr. Ayush Kumar Agarwal, who is currently the Director - Commercial Excellence.01-08-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Announcement under Regulation 30 (LODR)-Change in Management
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you on the change in role of Mr. Atul Tandon, Business Unit Head - Oncology. He will be transitioning from the said role with effect from close of business hours on July 31, 2023, as he takes up another responsibility within AstraZeneca group. In the interim, the Oncology Business Unit of the Company will be managed by Mr. Ayush Kumar Agarwal, who is currently the Director - Commercial Excellence.31-07-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation, 2015
This is to inform that AstraZeneca Pharma India Limited has received permission to Import Pharmaceutical Formulations of New Drug for Sale or for Distribution in Form CT-20 (Marketing Authorisation - Additional Indication) from the Drugs Controller General of India for Dapagliflozin Tablets 10 mg. Through this approval, Dapagliflozin Tablets 10 mg is indicated for the treatment of heart failure in adults. The receipt of this permission paves way for the launch of Dapagliflozin Tablets 10 mg in India for the specified indication, subject to the receipt of related statutory approvals and licenses.24-07-2023
ASTRAZENECA PHARMA INDIA LTD. - 506820 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, we would like to inform you that the Registrar and Transfer Agents of the Company, Integrated Registry Management Services Private Limited have informed the Company on the enclosed request for Loss of Share Certificate from the claimant.22-07-2023